ERBB2 and cancer: Additionally, HER2 Affibody binds the HER2 protein on the membrane of Trastuzumab-resistant HER2-overexpressing cells, suggesting the potential of NIR-PIT using HER2 Affibody–IR700Dye conjugate to treat Trastuzumab-resistant cancer [20].